Stephen W. LaFon

1.6k citations

26 papers · 1.2k indexed · h-index 18

Virology top 5%
- HIV Research and Treatment 5
Infectious Diseases top 5%
- HIV/AIDS drug development and treatment 10
- Tuberculosis Research and Epidemiology 4
Epidemiology top 5%
- Trypanosoma species research and implications 8
- Pneumocystis jirovecii pneumonia detection and treatment 7
Physiology top 5%
Parasitology top 5%
Molecular Biology
- Biochemical and Molecular Research 10
Public Health, Environmental and Occupational Health
- Research on Leishmaniasis Studies 8
Organic Chemistry
- Synthesis and Biological Evaluation 3

Co-authors: Donald J. Nelson J. Joseph Marr Randolph L. Berens Henry Masur Judith Falloon Danny J. Lancaster Thomas A. Krenitsky Gertrude B. Elion
Cited by: Virology Infectious Diseases Epidemiology
Journals: New England Journal of Medicine (2 papers)Journal of Biological Chemistry (2 papers)Clinical Infectious Diseases (1 paper)
Partner nations: United States United Kingdom Sweden

In The Last Decade

Stephen W. LaFon

26 papers receiving 1.1k citations

Peers

Countries citing papers authored by Stephen W. LaFon

Since Specialization

Citations

This map shows the geographic impact of Stephen W. LaFon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen W. LaFon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen W. LaFon more than expected).

Fields of papers citing papers by Stephen W. LaFon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen W. LaFon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen W. LaFon. The network helps show where Stephen W. LaFon may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Stephen W. LaFon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stephen W. LaFon Line = papers co-authored together Stephen W. LaFon links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Combination Therapy with Amprenavir, Abacavir, and Efavirenz in Human Immunodeficiency Virus (HIV)-Infected Patients Failing a Protease-Inhibitor Regimen: Pharmacokinetic Drug Interactions and Antiviral Activity Clinical Infectious Diseases ·Judith Falloon,Stephen C. Piscitelli,S Vogel,Brian M. Sadler,Hiroaki Mitsuya,Mark F. Kavlick,Kazuhisa Yoshimura,M. Brooke Rogers,Stephen W. LaFon,Douglas J. Manion,H. Clifford Lane,Henry Masur	2000	65
2	Use of Drug Effect Interaction Modeling with Monte Carlo Simulation To Examine the Impact of Dosing Interval on the Projected Antiviral Activity of the Combination of Abacavir and Amprenavir Antimicrobial Agents and Chemotherapy ·George L. Drusano,David Z. D’Argenio,Sandra L. Preston,Carlo Barone,William Symonds,Stephen W. LaFon,M. Brooke Rogers,William Prince,Alan Bye,John A. Bilello	2000	38
3	Atovaquone Suspension in HIV‐Infected Volunteers: Pharmacokinetics, Pharmacodynamics, and TMP‐SMX Interaction Study Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Judith Falloon,Susie Sargent,Stephen C. Piscitelli,Christine M. Bechtel,Stephen W. LaFon,Brian M. Sadler,Robert Walker,Joseph A. Kovacs,Michael A. Polis,Richard T. Davey,H. Clifford Lane,Henry Masur	1999	33
4	Safety and Pharmacokinetics of Abacavir (1592U89) following Oral Administration of Escalating Single Doses in Human Immunodeficiency Virus Type 1-Infected Adults Antimicrobial Agents and Chemotherapy ·Princy Kumar,Donna E. Sweet,James A. McDowell,William T. Symonds,Yu Lou,Seth Hetherington,Stephen W. LaFon	1999	54
5	Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults AIDS ·Michael S. Saag,Anders Sönnerborg,Ramón A. Torres,Danny J. Lancaster,Brian Gazzard,Robert T. Schooley,Carmen Romero,Dennis Kelleher,William Spreen,Stephen W. LaFon	1998	70
6	Effects of Aerosolized Synthetic Surfactant, Atovaquone, and the Combination of These on Murine Pneumocystis carinii Pneumonia The Journal of Infectious Diseases ·Walter T. Hughes,Elaine M. Sillos,Stephen W. LaFon,Michael J. Rogers,Joseph L. Woolley,Christine Davis,Scott D. Studenberg,Edward N. Pattishall,T. Freeze,Graham M. Snyder,Sharon Staton	1998	12
7	Adverse Events Associated with Trimethoprim-Sulfamethoxazole and Atovaquone during the Treatment of AIDS-Related Pneumocystis carinii Pneumonia The Journal of Infectious Diseases ·Walter T. Hughes,Stephen W. LaFon,John D. Scott,Henry Masur	1995	64
8	Clinical Experience with Atovaquone on a Treatment Investigational New Drug Protocol for Pneumocystis carinii Pneumonia Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology ·Alice White,Stephen W. LaFon,Michael M. Rogers,Elizabeth Andrews,Nathaniel Brown	1995	6
9	Comparison of Atovaquone (566C80) with Trimethoprim-Sulfamethoxazole to Treat Pneumocystis carinii Pneumonia in Patients with AIDS New England Journal of Medicine ·Walter Hughes,Gifford Leoung,Françoise Kramer,Samuel A. Bozzette,Sharon Safrin,Peter Frame,Nathan Clumeck,Henry Masur,Danny J. Lancaster,Charles K. Chan,James P. Lavelle,Joel Rosenstock,Judith Falloon,Judith Feinberg,Stephen W. LaFon,Michael J. Rogers,Fred R. Sattler	1993	204
10	Antiprotozoal activity of 3′-deoxyinosine Biochemical Pharmacology ·Allan R. Moorman,Stephen W. LaFon,Donald J. Nelson,Heidi H. Carter,J. Joseph Marr,Randolph L. Berens	1991	9
11	A Preliminary Evaluation of 566C80 for the Treatment of Pneumocystis Pneumonia in Patients with the Acquired Immunodeficiency Syndrome New England Journal of Medicine ·Judith Falloon,Joseph A. Kovacs,Walter Hughes,Donna O'neill,Michael A. Polis,Richard T. Davey,Michael J. Rogers,Stephen W. LaFon,Irwin M. Feuerstein,Danny J. Lancaster,Mack A. Land,Carmelita U. Tuazon,Michael N. Dohn,Stephen Greenberg,H. Clifford Lane,Henry Masur	1991	61
12	Prophylactically Administered Retrovir(R) in Health Care Workers Potentially Exposed to the Human Immunodeficiency Virus The Journal of Infectious Diseases ·Stephen W. LaFon,Sandra Nusinoff Lehrman,David W. Barry	1988	14
13	Antigiardial activity of guanine arabinoside mechanism studies Biochemical Pharmacology ·Richard L. Miller,Donald J. Nelson,Stephen W. LaFon,Wayne H. Miller,Thomas A. Krenitsky	1987	11
14	Inosine analogs. Their metabolism in mouse L cells and in Leishmania donovani. Journal of Biological Chemistry ·Stephen W. LaFon,Donald J. Nelson,Randolph L. Berens,J. Joseph Marr	1985	45
15	Purine metabolism in the intact sporozoites and merozoites of Eimeria tenella Molecular and Biochemical Parasitology ·Stephen W. LaFon,David J. Nelson	1985	11
16	Antileishmanial action of 4-thiopyrazolo (3,4-d)pyrimidine and its ribonucleoside Biochemical Pharmacology ·J. Joseph Marr,Randolph L. Berens,Donald J. Nelson,Thomas A. Krenitsky,Thomas Spector,Stephen W. LaFon,Gertrude B. Elion	1982	36
17	Purine and pyrimidine salvage pathways in Leishmania donovani Biochemical Pharmacology ·Stephen W. LaFon,Donald J. Nelson,Randolph L. Berens,J. Joseph Marr	1982	55
18	The metabolism of formycin B in Leishmaniadonovani Biochemical and Biophysical Research Communications ·Donald J. Nelson,Stephen W. LaFon,Thomas Jones,Thomas Spector,Randolph L. Berens,J. Joseph Marr	1982	39
19	Purine metabolism in Trypanosoma cruzi Molecular and Biochemical Parasitology ·Randolph L. Berens,J. Joseph Marr,Stephen W. LaFon,Donald J. Nelson	1981	69
20	Comparative Metabolism of a New Antileishmanial Agent, Allopurinol Riboside, in the Parasite and the Host Cell Advances in experimental medicine and biology ·Donald J. Nelson,Stephen W. LaFon,Gertrude B. Elion,J. Joseph Marr,Randolph L. Berens	1980	7

About Stephen W. LaFon

Stephen W. LaFon is a scholar working on Virology, Infectious Diseases and Epidemiology, having authored 26 papers that have together received 1.2k indexed citations. Recurring topics across this work include Biochemical and Molecular Research (10 papers), HIV/AIDS drug development and treatment (10 papers), Trypanosoma species research and implications (8 papers), Research on Leishmaniasis Studies (8 papers), Pneumocystis jirovecii pneumonia detection and treatment (7 papers), HIV Research and Treatment (5 papers), Tuberculosis Research and Epidemiology (4 papers) and Synthesis and Biological Evaluation (3 papers). The work is most often cited by research in Virology (189 citations), Infectious Diseases (552 citations) and Epidemiology (720 citations). Stephen W. LaFon has collaborated with scholars based in United States, United Kingdom and Sweden. Frequent co-authors include Donald J. Nelson, J. Joseph Marr, Randolph L. Berens, Henry Masur, Judith Falloon, Danny J. Lancaster, Thomas A. Krenitsky, Gertrude B. Elion, Richard L. Miller and Wayne H. Miller. Their work appears in journals such as New England Journal of Medicine, Journal of Biological Chemistry and Clinical Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact